Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
04:30pm, Monday, 22'nd Apr 2024
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
04:30pm, Wednesday, 10'th Apr 2024
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
04:30pm, Friday, 22'nd Dec 2023
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Cellectis' Shareholders Meeting to be Held on December 22, 2023
04:30pm, Friday, 17'th Nov 2023
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
02:30am, Wednesday, 15'th Nov 2023
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subs
Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript
02:22pm, Tuesday, 07'th Nov 2023
Cellectis SA (NASDAQ:CLLS ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frat
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
04:30pm, Monday, 06'th Nov 2023
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
06:57pm, Friday, 03'rd Nov 2023
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
04:30pm, Wednesday, 01'st Nov 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
5 Most Active Penny Stocks Today & Why They're Moving Now
02:11pm, Wednesday, 01'st Nov 2023
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Why Is Cellectis (CLLS) Stock Up 175% Today?
08:13am, Wednesday, 01'st Nov 2023
Cellectis (NASDAQ: CLLS ) stock is taking off on Wednesday after the company announced an investment from AstraZeneca (NASDAQ: AZN ). Cellectis and AstraZeneca have signed a strategic collaboratio
Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca
07:29am, Wednesday, 01'st Nov 2023
The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 m
